The Association Between Different Monocyte Subsets and Coronary Collateral Development

Coronary Artery Disease Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01356836
• Other study ID #: Monocyte subsets
• Status: Completed
• Phase: N/A
• First received: May 17, 2011
• Last updated: May 19, 2011
• Start date: January 2011
• Est. completion date: May 2011

Study information

• Verified date: March 2011
• Source: Yuksek Ihtisas Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Turkish Ministry of Health
• Study type: Observational

Clinical Trial Summary

Collateral growth and coronary angiogenesis are chronic adaptations to myocardial ischemia. Collateralization helps to restore blood flow and as a result salvages myocardium in severely ischemic myocardial regions. Thus, good collateral development in patients with severe coronary artery disease (CAD) improves ventricular function and prognosis (1-3).

However, coronary collateral development is different among patients even with similar degrees of coronary artery stenosis. Several factors, such as diabetes mellitus (4) and duration of myocardial ischemic symptoms (5) have been reported to effect coronary collateral development. At the cellular level, inflammatory cells, especially monocytes have an important role in collateralization. In a series of experimental studies with animals, it has been shown that monocytes are important elements for development of collateral vessels (6-7). In a recent study, it has been demonstrated that increased circulating monocyte count is related to good collateral development in patients with stable coronary artery disease (8).

Monocytes in human blood are heterogeneous and can be classified into two subsets according to the presence or absence of the FcγRIII receptor CD16 (9): CD14++CD16- monocytes characterized by high level expression of the CD14 cell surface receptor but no expression of CD16 receptor, and CD14+CD16+ monocytes characterized by the co-expression of CD16 receptor with either high or low level expression of the CD14 receptor. These subsets differ in function and response to several cytokines.

Our aim in this study was to find out any possible relationship between the levels of circulating monocyte subsets and coronary collateral development.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• > 95% stenosis of at least one major coronary artery in their first coronary angiogram

Exclusion Criteria:

• previous percutaneous or surgical revascularization history

• evidence of ongoing infection and inflammation

• known malignancy and chronic kidney disease (serum creatinine > 1.5 mg/dl

• diabetic patients

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Coronary Ischemia
• Myocardial Ischemia

Locations

Country	Name	City	State
Turkey	1Türkiye Yüksek Ihtisas Education and Research Hospital, Department of Cardiology	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Yuksek Ihtisas Hospital

Country where clinical trial is conducted

Turkey,